WO1999061010A2 - Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound - Google Patents
Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound Download PDFInfo
- Publication number
- WO1999061010A2 WO1999061010A2 PCT/EP1999/003138 EP9903138W WO9961010A2 WO 1999061010 A2 WO1999061010 A2 WO 1999061010A2 EP 9903138 W EP9903138 W EP 9903138W WO 9961010 A2 WO9961010 A2 WO 9961010A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meiosis
- compound
- increasing
- use according
- hypoxanthine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a pharmaceutical composition and its use to treat infertility.
- Meiosis is the unique and ultimate event of germ cells on which sexual reproduction is based. Meiosis comprises two meiotic divisions. During the first division, exchange between maternal and paternal genes take place before the pairs of chromosomes are separated into the two daughter cells. These contain only half the number (1 n) of chromosomes and 2c DNA. The second meiotic division proceeds without a DNA synthesis. This division therefore results in the formation of the hapioid germ cells with only 1c DNA.
- the meiotic events are similar in the male and female germ cells, but the time schedule and the differentiation processes which lead to ova and to spermatozoa differ profoundly. All female germ cells enter the prophase of the first meiotic division early in life, often before birth, but all are arrested as oocytes later in the prophase
- Cyclic adenosine 5 ' -monophosphate plays a pivotal role as a second messenger in the signal transduction pathway during meiosis in the oocyte
- cAMP is generated by the action of adenylate cyclase (AC).
- AC adenylate cyclase
- cAMP is degraded by the family of phosphodiesterase enzymes (PDE), which produces inactive second messenger products
- Hypoxanthine is an inhibitor of cAMP PDE (Eppig, J J et al (1985) Biol Reprod. 33 1041-1049). As such, it can prevent the hydrolysis of oocyte cAMP and thereby maintain elevated levels of cAMP in the oocyte.
- agents acting upstream or downstream of cAMP are able to increase cAMP levels.
- activation of AC with forskolin inhibition of PDE with the nonselective 3- isobutyl-1-methyixanth ⁇ ne (lBMX) or inhibition of the oocyte-specific isoform PDE3 with a specific PDE3- ⁇ nhib ⁇ tor, e.g mii ⁇ none, leads to meiotic arrest by maintaining elevated levels of c-AMP within the oocytes (Downs SM and Hunzicker-Dunn M (1995) Dev Biol 172. 72-85, Tsafin A et al (1996) Dev Biol 178. 393-402)
- a PDE3 specific inhibitor has been described as a contraceptive agent (WO98/10765).
- the present invention provides a pharmaceutical composition comprising c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility in mammals, particulary in humans, more particulary in females.
- c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility in mammals, particulary in humans, more particulary in females.
- the increase of fertility by low dose c-AMP- increasing compounds is surprising since the teaching of the prior art is that c-AMP- increasing compounds are responsible for meiotic arrest and a PDE3 specific inhibitor has even been used as a contraceptive agent.
- the combination of the low dose cAMP-increasing compounds with at least one meiosis-stimulating compound shows a significantly higher stimulation rate than the meiosis-stimulating compound(s) alone.
- the invention relates to the use of low dose c-AMP- increasing compounds alone or in combination with at least one meiosis-stimulating compound as active substances for the production of a pharmaceutical composition for the treatment of infertility in mammals, particular in humans, more particularly in females.
- Low dose c-AMP-increasing compounds alone increase the fertilization rate compared to the control where no compounds were added and the combination of c- AMP-increasing compounds in a low dose with a meiosis-stimulating compound shows an even higher rate of fertilization than the meiosis-stimulating compound alone or the low dose c-AMP-increasing compound alone.
- the invention relates to the use of low dose c-AMP- increasing compounds alone or in combination with at least one meiosis-stimulating compound to increase the rate of fertilization in a mammal, particularly in humans, more particularly in females.
- This use may be to regulate the fertilization rate in a fertilization culture media.
- the invention includes the use of a low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound for the administration to a germ cell.
- the germ ceil may be an oocyte or a spermatozoon.
- the invention in another embodiment relates to a method of stimulating meiosis in a mammalian germ ceil comprising administering ex vivo or in vivo or in vitro to a germ cell in need of such a stimulation an effective amount of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound.
- the germ cell may be an oocyte or a spermatozoon.
- the invention in a further embodiment relates to a pharmaceutical kit comprising a dosage unit for a c-AMP-increasing compound in low dose and a dosage unit of at least one meiosis-stimulating compound.
- the c-AMP-increasing compound and the meiosis-stimulating compound may be provided in the same application form or in different application forms.
- Application forms means e.g. tablets, liquid compositions for injections, paste and others well known in the art.
- Meiosis-stimulating compounds according to the present invention are all compounds that can activate meiosis. Compounds being known to stimulate meiosis and their synthesis are described, i.e., in WO 96/27658, WO97/00884, WO96/00235, W098/28323 and W098/52965. In preferred embodiments of all modes of the invention the meiosis-stimulating compound is FF-MAS (4,4-dimethyl-5 ⁇ -cholesta- 8,14,24-trien-3 ⁇ -ol).
- the stimulation rate is at least 40 - 50 %, preferred 50 - 75%, and more preferred 75 - 100 %.
- Low dose cAMP-increasing compounds according to the present invention is a dose of cAMP-increasing compounds that lead to meiotic maturation without inducing meiotic arrest.
- the cAMP- increasing compounds are applied in a dose below 3mM, more preferred in a dose of 0.003 - 1 mM, and especially preferred in a dose of 0.1-0.5mM.
- the cAMP- increasing compounds are purines, unspecific PDE-inhibitors, specific PDE 3 - inhibitors or synthetic membrane permeable cAMP.
- a purine is e.g. hypoxanthine or adenosine.
- Unspecific PDE-inhibitors are nonselective inhibitors which inhibit all types of PDEs, e.g. IBMX, theophylline or SQ20,006 (1-ethyl-4-hydrazino-14- pyrazolo-(3,4-b)-pyridine-5-carboxylicacidethyiester).
- PDE3 inhibitors examples include milrinone, cilostamide, amrinone, enoximone, lixazinone, indolidan and other inhibitors as listed in WO98/10765. This reference also gives the methods of preparation of these compounds.
- An example for a synthetic membrane permeable cAMP is dibutyryl-c-AMP (dbcAMP).
- the meiosis-stimulating compound is FF-MAS and the cAMP-increasing compound is a purine, preferably hypoxanthine.
- compositions may comprise pharmaceutically acceptable excipients well known in the art like carriers, diluents, absorption enhancers, preservatives, buffers, agents for adjusting the osmotic pressure, tablet disintegrating agents and other ingredients which are conventionally used in the art.
- solid carriers are magnesium carbonate, magnesium stearate, dextrin, lactose, sugar, talc, gelatin, pectin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, low melting waxes and cacao butter.
- Liquid compositions include sterile solutions, suspensions and emulsions.
- Such liquid compositions may be suitable for injection or for use in connection with ex vivo, in vivo ,and in vitro fertilization.
- the liquid compositions may contain other ingredients which are conventionally used in the art, some of which are mentioned in the list above.
- a composition for transdermal administration of a compound of this invention may be provided in the form of a patch
- a composition for nasal administration may be provided in the form of a nasal spray in liquid or powder form
- a composition for intra-vaginal administration may be provided in the form of a tampon or other intra-vaginal devices.
- the dosage to be administered depends to a large extent on the condition and the size of the subject being treated as well as the frequency of treatment and the route of administration.
- compositions of the invention are prepared by intimately bringing into association the active compound or compounds with the liquid or solid auxiliary ingredients and then, if necessary, shaping the product into the desired formulation.
- Example 1 Test of hypoxanthine, FF-MAS and the combination of FF-MAS and hypoxanthine in the oocyte assay
- Naked oocytes (NO) and cumulus enclosed oocytes (CEO) were isolated from follicles from immature (C57B1/6J x DBA/2J)F ⁇ mice (age 21-24 days), that had received 10 I.U. PMSG i.p. 48h prior to collection.
- the oocytes were cultured in 4- well multidishes in a modified ⁇ -MEM medium containing 1mg fetuin/ml culture medium. Each well contained 0.4 ml of the oocyte culture medium and 35-45 oocytes.
- the control and test cultures were made with different concentrations of the compounds to be tested as indicated in the tables.
- the cultures were kept at 37°C and 100% humidity with 5% C0 2 in the air for 18 hours.
- Oocytes arrested in meiosis are characterised by an intact nucleus with a prominent nucleolus, known as germinal vesicle (GV).
- GV germinal vesicle
- Table 1 Activation of meiosis in oocytes using FF-MAS, low dose hypoxanthine and the combination of FF-MAS + hypoxanthine
- GVB germinal vesicle breakdown
- n number of
- hypoxanthine used was obtained from Sigma, Deisenhofen, Germany. Similar to the control, low dose hypoxanthine (0.4mM) is able to lead to meiotic maturation in most oocytes. However, 3mM hypoxanthine nearly completely prevents meiotic maturation. It is evident that FF-MAS not only when given together with a meiosis - inhibiting dose of hypoxanthine (3mM), but also when given together with low dose hypoxanthine (0.4mM) is able to lead to meiotic maturation in nearly all oocytes.
- Example 2 Test of hypoxanthine, FF-MAS and the combination of FF-MAS and hypoxanthine in the in-vitro fertilization (IVF) assay
- GVB germinal vesicle breakdown
- hypoxanthine used was obtained from Sigma, Deisenhofen, Germany. Oocytes cultured in the presence of 3mM hypoxanthine were unable to get fertilized. 0.4mM hypoxanthine and 10 ⁇ M FF-MAS + 3 mM hypoxanthine increased the fertilization rate of the control group by about 50%. However, the combination of 10 ⁇ M FF-MAS + 0.4 mM hypoxanthine could nearly double the control IVF-rate.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99939972A EP1098652A2 (en) | 1998-05-26 | 1999-05-07 | Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound |
KR1020007013278A KR20010043828A (en) | 1998-05-26 | 1999-05-07 | Treatment of Infertility with cAMP-Increasing Compounds Alone or in Combination with at Least One Meiosis-Stimulating Compound |
AU54089/99A AU5408999A (en) | 1998-05-26 | 1999-05-07 | Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound |
JP2000550470A JP2002516272A (en) | 1998-05-26 | 1999-05-07 | Fertility treatment with a compound that increases cAMP alone or in combination with at least one compound that stimulates meiosis |
CA002333320A CA2333320A1 (en) | 1998-05-26 | 1999-05-07 | Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound |
NO20005954A NO20005954D0 (en) | 1998-05-26 | 2000-11-24 | Treatment of infertility with cAMP-increasing compounds alone or in combination with at least one meiosis stimulant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98250177 | 1998-05-26 | ||
EP98250177.7 | 1998-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999061010A2 true WO1999061010A2 (en) | 1999-12-02 |
WO1999061010A3 WO1999061010A3 (en) | 2000-04-27 |
Family
ID=8234594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/003138 WO1999061010A2 (en) | 1998-05-26 | 1999-05-07 | Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1098652A2 (en) |
JP (1) | JP2002516272A (en) |
KR (1) | KR20010043828A (en) |
AU (1) | AU5408999A (en) |
CA (1) | CA2333320A1 (en) |
NO (1) | NO20005954D0 (en) |
WO (1) | WO1999061010A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001038493A1 (en) * | 1999-11-25 | 2001-05-31 | Novo Nordisk A/S | Treatment of human infertility |
WO2001062258A2 (en) * | 2000-02-25 | 2001-08-30 | Schering Aktiengesellschaft | Improvement of implantation rate using ff-mas |
WO2001062260A2 (en) * | 2000-02-25 | 2001-08-30 | Schering Aktiengesellschaft | Improvement of implantation rate |
WO2001076360A2 (en) * | 2000-04-06 | 2001-10-18 | Novo Nordisk A/S | Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro |
EP1147774A1 (en) * | 2000-04-20 | 2001-10-24 | Stichting Dienst Landbouwkundig Onderzoek | Method for improving the quality of sperm for artificial insemination of animals |
WO2001088098A2 (en) * | 2000-05-18 | 2001-11-22 | Schering Aktiengesellschaft | Fertilization of aged oocytes |
US6544166B1 (en) | 1999-11-25 | 2003-04-08 | Groendahl Christian | Treatment of human infertility |
WO2003051344A1 (en) * | 2001-12-14 | 2003-06-26 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation_using a non-polypeptide camp level modulator |
WO2003070766A2 (en) * | 2002-02-22 | 2003-08-28 | Novo Nordisk A/S | A transducer of mas signalling |
US6844313B1 (en) | 1999-09-16 | 2005-01-18 | Novo Nordisk A/S | Composition containing a meiosis activating substance |
US6916921B2 (en) | 2001-03-26 | 2005-07-12 | Schering Ag | Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds |
WO2013030302A1 (en) | 2011-08-30 | 2013-03-07 | Centre National De La Recherche Scientifique | Protein complex comprising mcm8 and mcm9 proteins and their use |
WO2013054111A1 (en) * | 2011-10-10 | 2013-04-18 | University Of Dundee | Improved sperm function/activity |
CN108531447A (en) * | 2018-04-13 | 2018-09-14 | 上海市计划生育科学研究所 | Adjust the compound and application thereof of Sperm Motility and supplementary reproduction |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0196530A2 (en) * | 1985-03-26 | 1986-10-08 | CTA Finanz AG | Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals |
WO1996000235A1 (en) * | 1994-06-23 | 1996-01-04 | Novo Nordisk A/S | Sterol derivatives used for regulation of meiosis |
WO1996027658A1 (en) * | 1995-03-06 | 1996-09-12 | Novo Nordisk A/S | Stimulation of meiosis |
WO1998004366A1 (en) * | 1996-07-26 | 1998-02-05 | Cauldron Limited Partnership | Removal of material by radiation applied at an oblique angle |
US5882928A (en) * | 1997-03-11 | 1999-03-16 | Oocytechs Research Corporation | In vitro maturation and fertilization of mammalian oocytes |
-
1999
- 1999-05-07 EP EP99939972A patent/EP1098652A2/en not_active Withdrawn
- 1999-05-07 AU AU54089/99A patent/AU5408999A/en not_active Abandoned
- 1999-05-07 CA CA002333320A patent/CA2333320A1/en not_active Abandoned
- 1999-05-07 JP JP2000550470A patent/JP2002516272A/en active Pending
- 1999-05-07 KR KR1020007013278A patent/KR20010043828A/en not_active Application Discontinuation
- 1999-05-07 WO PCT/EP1999/003138 patent/WO1999061010A2/en not_active Application Discontinuation
-
2000
- 2000-11-24 NO NO20005954A patent/NO20005954D0/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0196530A2 (en) * | 1985-03-26 | 1986-10-08 | CTA Finanz AG | Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals |
WO1996000235A1 (en) * | 1994-06-23 | 1996-01-04 | Novo Nordisk A/S | Sterol derivatives used for regulation of meiosis |
WO1996027658A1 (en) * | 1995-03-06 | 1996-09-12 | Novo Nordisk A/S | Stimulation of meiosis |
WO1998004366A1 (en) * | 1996-07-26 | 1998-02-05 | Cauldron Limited Partnership | Removal of material by radiation applied at an oblique angle |
US5882928A (en) * | 1997-03-11 | 1999-03-16 | Oocytechs Research Corporation | In vitro maturation and fertilization of mammalian oocytes |
Non-Patent Citations (9)
Title |
---|
BYSKOV A G ET AL: "CHEMICAL STRUCTURE OF STEROLS THAT ACTIVATE OOCYTE MEIOSIS" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 374, no. 6522, 6 April 1995 (1995-04-06), pages 559-562, XP002043016 ISSN: 0028-0836 cited in the application * |
CARROLL J ET AL: "Effect of dibutyryl cyclic adenosine monophosphate on granulosa cell proliferation, oocyte growth and meiotic maturation in isolated mouse primary ovarian follicles cultured in collagen gels." JOURNAL OF REPRODUCTION AND FERTILITY, (1991 MAY) 92 (1) 197-207. , XP000874962 * |
DIENHART, MARY K. ET AL: "Cyclic AMP reversal of hypoxanthine-arrested preimplantation mouse embryos is EDTA-dependent" ZYGOTE (1996), 4(2), 129-137 , XP000874771 * |
HARADA, M. ET AL: "Bovine oocytes from early antral follicles grow to meiotic competence in vitro: Effect of FSH and hypoxanthine." THERIOGENOLOGY, (1997) VOL. 48, NO. 5, PP. 743-755. , XP000874856 * |
OTTESEN, JAN L. ET AL: "The effect of meiosis activating sterol (MAS) and some oxysterols on the resumption of meiosis in mouse oocytes cultured in vitro." BIOLOGY OF REPRODUCTION, (1997) VOL. 56, NO. SUPPL. 1, PP. 97. MEETING INFO.: THIRTIETH ANNUAL MEETING OF THE SOCIETY FOR THE STUDY OF REPRODUCTION PORTLAND, OREGON, USA AUGUST 2-5, 1997 , XP000874956 * |
RUAN, BENFANG ET AL: "Sterols affecting meiosis: novel chemical syntheses and the biological activity and spectral properties of the synthetic sterols" J. LIPID RES. (1998), 39(10), 2005-2020 , XP000874959 * |
WARIKOO P K ET AL: "Hypoxanthine and cyclic adenosine 5'-monophosphate maintain meiotic arrest of rhesus monkey oocytes in vitro." FERTILITY AND STERILITY, (1989 MAY) 51 (5) 886-9. , XP000874960 * |
WIERSMA A ET AL: "SPECIFIC PHOSPHODIESTERASE 3 INHIBITORS PREVENT THE RESUMPTION OF MEIOSIS IN MOUSE OOCYTES IN VITRO" BIOLOGY OF REPRODUCTION,US,ORLANDO, FL, vol. 56, no. SUPPL. 01, 1997, page 91 XP000874782 ISSN: 0006-3363 * |
WIERSMA, A. ET AL: "Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents" J. CLIN. INVEST. (1998), 102(3), 532-537 , XP000874944 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6844313B1 (en) | 1999-09-16 | 2005-01-18 | Novo Nordisk A/S | Composition containing a meiosis activating substance |
WO2001038493A1 (en) * | 1999-11-25 | 2001-05-31 | Novo Nordisk A/S | Treatment of human infertility |
US6544166B1 (en) | 1999-11-25 | 2003-04-08 | Groendahl Christian | Treatment of human infertility |
WO2001062260A3 (en) * | 2000-02-25 | 2002-04-04 | Schering Ag | Improvement of implantation rate |
WO2001062258A3 (en) * | 2000-02-25 | 2002-03-07 | Schering Ag | Improvement of implantation rate using ff-mas |
WO2001062260A2 (en) * | 2000-02-25 | 2001-08-30 | Schering Aktiengesellschaft | Improvement of implantation rate |
WO2001062258A2 (en) * | 2000-02-25 | 2001-08-30 | Schering Aktiengesellschaft | Improvement of implantation rate using ff-mas |
WO2001076360A2 (en) * | 2000-04-06 | 2001-10-18 | Novo Nordisk A/S | Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro |
WO2001076360A3 (en) * | 2000-04-06 | 2002-01-24 | Novo Nordisk As | Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro |
US7192768B2 (en) | 2000-04-06 | 2007-03-20 | Novo Nordisk A/S | Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro |
EP1147774A1 (en) * | 2000-04-20 | 2001-10-24 | Stichting Dienst Landbouwkundig Onderzoek | Method for improving the quality of sperm for artificial insemination of animals |
WO2001080867A1 (en) * | 2000-04-20 | 2001-11-01 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Method for improving the quality of sperm for artificial insemination of animals |
US6890708B2 (en) | 2000-04-20 | 2005-05-10 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Method for improving the quality of sperm for artificial insemination of animals |
WO2001088098A2 (en) * | 2000-05-18 | 2001-11-22 | Schering Aktiengesellschaft | Fertilization of aged oocytes |
WO2001088098A3 (en) * | 2000-05-18 | 2002-05-16 | Schering Ag | Fertilization of aged oocytes |
US6916921B2 (en) | 2001-03-26 | 2005-07-12 | Schering Ag | Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds |
WO2003051344A1 (en) * | 2001-12-14 | 2003-06-26 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation_using a non-polypeptide camp level modulator |
EA011213B1 (en) * | 2001-12-14 | 2009-02-27 | Лаборатуар Сероно Са | Method of inducing ovulation in a female host administering inhibitors of phosphodiesterase 4 isoforms (pde4) |
US7507707B2 (en) | 2001-12-14 | 2009-03-24 | Laboratoires Serono Sa | Methods of inducing ovulation using a non-polypeptide camp level modulator |
EP1908463A3 (en) * | 2001-12-14 | 2009-11-25 | Merck Serono SA | Methods of inducing ovulation using a non-polypeptide camp level modulator |
WO2003070766A3 (en) * | 2002-02-22 | 2003-12-24 | Novo Nordisk As | A transducer of mas signalling |
WO2003070766A2 (en) * | 2002-02-22 | 2003-08-28 | Novo Nordisk A/S | A transducer of mas signalling |
WO2013030302A1 (en) | 2011-08-30 | 2013-03-07 | Centre National De La Recherche Scientifique | Protein complex comprising mcm8 and mcm9 proteins and their use |
WO2013054111A1 (en) * | 2011-10-10 | 2013-04-18 | University Of Dundee | Improved sperm function/activity |
CN108531447A (en) * | 2018-04-13 | 2018-09-14 | 上海市计划生育科学研究所 | Adjust the compound and application thereof of Sperm Motility and supplementary reproduction |
Also Published As
Publication number | Publication date |
---|---|
EP1098652A2 (en) | 2001-05-16 |
NO20005954L (en) | 2000-11-24 |
CA2333320A1 (en) | 1999-12-02 |
WO1999061010A3 (en) | 2000-04-27 |
KR20010043828A (en) | 2001-05-25 |
AU5408999A (en) | 1999-12-13 |
JP2002516272A (en) | 2002-06-04 |
NO20005954D0 (en) | 2000-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999061010A2 (en) | Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound | |
US5830757A (en) | Stimulation of Meiosis | |
AU764452B2 (en) | Method of promoting cervical and vaginal secretions | |
EP1156821B1 (en) | Treatment of infertility | |
EP1156822B1 (en) | Iin vitro method for synchronisation of oocyte maturation | |
US20080311656A1 (en) | Meiosis arrest in oocytes in vitro | |
EP1235899B1 (en) | Treatment of human infertility | |
US6544166B1 (en) | Treatment of human infertility | |
MXPA00009505A (en) | TREATMENT OF INFERTILITY WITH cAMP-INCREASING COMPOUNDS ALONE OR IN COMBINATION WITH AT LEAST ONE MEIOSIS-STIMULATING COMPOUND | |
Roy et al. | In vitro inhibition of trophoblast maturation and expansion of early rat blastocysts by an oestrogen antagonist | |
Uche‐Nwachi | Effect of intramuscular sulfadoxine‐pyrimethamine on pregnant Wistar rats | |
WO2001062260A2 (en) | Improvement of implantation rate | |
EP1272618A2 (en) | Synchronization of the cytoplasmatic and nuclear maturation of oocytes in vitro | |
WO1997000883A1 (en) | Meiosis regulating compounds | |
US20030153808A1 (en) | Implantation rate using ff-mas | |
WO2001088098A2 (en) | Fertilization of aged oocytes | |
CA2335329A1 (en) | Meiosis regulating compounds | |
MXPA97006565A (en) | Stimulation of meio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999939972 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/009505 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2333320 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09701026 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007013278 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999939972 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007013278 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999939972 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007013278 Country of ref document: KR |